Effects on the Human Body of a Dietary Supplement Containing L-Carnitine and *Garcinia cambogia* Extract: A Study using Double-blind Tests

Yoshikazu Yonei^{1,*}, Yoko Takahashi¹, Sawako Hibino¹, Miwako Watanabe²,
and Toshito Yoshioka³

¹Anti-Aging Medical Research Center, Doshisha University, Kyoto 610-0394, Japan

²Mareesia Garden Clinic, Tokyo 163-1011, Japan

³Waseda University Graduate School of Commerce, Tokyo 165-8050, Japan

Received 13 March, 2006; Accepted 20 February, 2007

Summary The effect of a dietary supplement with L-carnitine (600 mg/day) and *Garcinia cambogia* extract (500 mg/day as hydroxycitric acid) as main ingredients was studied in 35 healthy volunteers {48.3 ± 6.9 years, body mass index (BMI): 26.3 ± 1.7} in a double-blind test (18 subjects in the Test Group and 17 in the Control Group). The yearly examination includes the standard yearly medical tests done in Japan, tests for assessing hormonal age, and a survey for assessing physical and mental fitness of the subjects, called the Anti-Aging QOL Common Questionnaire (AAQOL). Use of this supplement significantly improved the level of lipid peroxides (−12.8%) in the blood as well as physical symptoms such as “tired eyes,” “blurry eyes,” “muscle pain/stiffness,” “early satiety,” “epigastralgia,” “dizziness,” “arthralgia” and “easily breaking into a sweat.” The Control Group showed a significantly favorable improvement rate, especially for “dizziness.” On the other hand, groups of subjects using the test compounds saw a significant rise in total cholesterol (4.5%), fasting blood sugar (4.1%) and HbA1c (3.4%). Our findings suggest that the consumption of the supplement can reduce the oxidative damage; however, the effect on QOL was equivocal. *Garcinia cambogia* extract did not show dietary efficacy.

Key Words: exercise, total cholesterol, body fat, insulin, 8-OHdG

Introduction

The objective of anti-aging medicine is to live as long as possible in good health. It is medical treatment that not only prolongs human life, but also enables a person to live a healthy and happy life, maintain quality of life (QOL), and reduce the physical and mental deterioration of aging [1]. Medically, anti-aging medicine is classified as prophylactic

medicine. Checkups and screenings for assessing the degree of aging are offered in Japan; a range of treatment options is available including diet, exercise, other lifestyle therapies, and drug therapies including nutritional supplement therapies and hormone replacement therapies.

Terms such as integrated medicine, alternative healthcare, Chinese herbal medicine, acupuncture therapy, and anti-aging medicine have been discussed in recent years, and numerous treatment methods are being proposed that differ from conventional Western medicine. Although numerous reports cite the efficacy of such treatment methods, the parameters used differ from one study to another. General physicians are currently left with the basic question, “To

*To whom correspondence should be addressed
Tel: +81-75-391-5644 Fax: +81-3-5730-1447
E-mail: yyonei@mail.doshisha.ac.jp

what degree are these treatments effective, and for what types of symptoms and diseases?"

The authors have used common parameters to investigate and study (a) the assessments of general physical examinations, (b) the physical and psychological influence as well as safety of dietary supplements, health foods, medical devices, exercise equipment, and cosmetics, and (c) obesity [2–4]. Our findings are shedding more light on the efficacies, limitations, and the range of effects of these products. Amino acids, in particular, exert a variety of influences on the body, and we have therefore conducted studies on health foods containing amino acids. In this study, we have focused on a food product for which one manufacturer has made health claims; the product contains L-carnitine, a type of amino acid, and *Garcinia cambogia* extract (65% hydroxycitric acid) manufactured by Nurex Corporation, Osaka; hereinafter referred to as "the Product". We studied, using healthy middle-aged and older subjects, the effects of the Product on the body as a double-blind, non-cross-matching test. We also studied parameters that are deemed especially important to anti-aging medicine, for the purpose of determining whether or not the use of the Product enhances QOL in people aged in their 40s to 60s.

Experimental Procedures

Subjects

The subjects of our study were healthy individuals aged in their 40s to 60s, with a BMI of 24 or higher, who had provided us with their written consent to participate in this study. The following individuals were excluded:

- those taking hormones, anti-osteoporosis drugs, and other medications
- those with diabetes, marked hepatic dysfunction, or other chronic diseases
- those with severe liver, kidney, heart, and/or blood diseases and other complications
- other individuals judged by a physician as unfit to participate in the study

Prior to the start of the test, we provided potential test subjects a thorough explanation not only of the duration, place, content, and methods of the test, but also on the benefits anticipated to be gained from participating in the study as well as disadvantages that may occur. The test subjects were assured that participation was completely voluntary, and that they would not suffer any disadvantages whatsoever, if they decided mid-way to withdraw from the testing, for any reason. The method of taking the Product was explained to all test participants by Nurex Corporation, either in writing or by holding an explanatory meeting.

Design

The period of the test was determined to be 8 weeks from

October 3 to November 28, 2004. Before and after the test, the following items were measured at the Mareesia Garden Clinic, Tokyo.

- physical measurements: Height (cm), weight (kg), body fat percentage, systolic and diastolic blood pressures and others
- blood tests: Platelet count ($10^4/\mu\text{l}$), erythrocyte count (RBC, $10^4/\mu\text{l}$), leukocyte count (WBC, $/\mu\text{l}$), hemoglobin content (HGB, g/dl), hematocrit (HCT, %), glutamate-oxaloacetate transaminase, glutamate-pyruvate transaminase (GOT, GPT, IU/l), γ -glutamyl transpeptidase (γ -GTP, IU/l), alkaline phosphatase (ALP, IU/l), creatinine phosphokinase (CPK, mU/ml), C-reactive protein (CRP, mg/dl), blood urea nitrogen (BUN, mg/dl), blood creatinine (Cr, mg/dl), uric acid (UA, mg/dl), total cholesterol (T-Chol, mg/dl), HDL-cholesterol (HDL-C, mg/dl), LDL-cholesterol (LDL-C, mg/dl), triglycerides (TG, mg/dl), fasting blood sugar (FBS, mg/dl), glycohemoglobin A1C (HbA1c), lactic acid (mg/dl), cortisol, dehydroepiandrosterone sulfate (DHEA-s), IGF-I, insulin, lipid peroxides (LPO, nmol/ml), electrolytes: sodium (Na, mEq/l), potassium (K^+ , mEq/l), and chloride (Cl^- , mEq/l).
- urine tests: Urinary 8-hydroxy-deoxyguanosine (8-OHdG) and urinary isoprostane
- observations on improvement of QOL using a common questionnaire sheet

If circumstances such as the following occurred, necessitating discontinuation of the test, the test was discontinued immediately, following the decision of the physician in charge of the test, and adequate treatment was provided.

- if other serious diseases are seen to have developed
- if existing symptoms (including complications) worsened
- if a physician determines that continuation of the test is impossible for other reasons

Our present study targeted 35 healthy individuals (18 men and 17 women) $\{48.3 \pm 6.9$ years, body mass index (BMI): $26.3 \pm 1.7\}$ who were randomly divided into the Test Group and the Control Group. At least 6 cases in each group are necessary for detection of the significant difference in any of more than 50 items in the Anti-Aging QOL Common Questionnaire (AAQol) [2–4], and the number should be doubled or tripled for the classified analysis according to 2 or 3 classes. There were 18 individuals in the Test Group (age: 48.6 ± 6.0 years, height: 163.1 ± 7.9 cm; weight: 69.9 ± 7.2 kg, and BMI: 26.3 ± 1.7 ; mean $\pm$ SD), and 17 in the Control Group (age: 48.0 ± 7.9 years, height: 163.5 ± 11.2 cm, weight: 66.5 ± 11.9 kg, and BMI: 24.7 ± 2.9 ; mean $\pm$ SD). The Test Group took 6 doses of the Product, including L-carnitine (600 mg/day) and *Garcinia cambogia* extract (500 mg/day as hydroxycitric acid) for 8 weeks, while the Control Group took 6 doses of a placebo drug for

8 weeks. The method of taking these test drugs was explained by a nutritionist to all of the test subjects.

The Product is manufactured by Nurex Corporation of Osaka Prefecture, Japan, and has the following composition.

Raw materials:

L-carnitine, L-tartrate, *Garcinia cambogia* extract, corn starch, edible purified oil-processed fat and oil (hydrogenated oil), gelatin, caramel coloring, calcium pantothenate, vitamin B₁. Nutritional ingredients (for every 3 doses of the Product): calories: 4.58 kcal, protein: 0.38 g, fat: 0.06 g, carbohydrates: 0.61 g, sodium: 1.26 mg, vitamin B₁: 1.2 mg, pantothenic acid: 10 mg, L-carnitine: 300 mg, hydroxycitric acid (*Garcinia cambogia* extract): 250 mg. The amounts of vitamin B₁ and pantothenic acid are subtle compared with those of daily dietary intake.

As indicators for the degree of oxidation stress, we used serum lipid peroxide, 8-OHdG (8-hydroxy-2' deoxyguanosine), and isoprostane (8-isoprostane F-2 α) [5–7]. These indicators were measured at the Japan Institute for the Control of Aging. Moreover, the 8-OHdG, isoprostane, and creatinine contained in the first urine in the early morning were measured to calculate the rate of 8-OHdG/CRE · isoprostane production and the creatinine correction volume (8-OHdG/CRE · isoprostane/CRE), based on the volume of urine and urine collection period (the time from the last urination of the previous night to the first urination the following morning).

Subjective symptoms were divided into physical and mental symptoms and evaluated on a scale of 1 to 5, using the Anti-Aging QOL Common Questionnaire (AAQol) [2–4].

Statistical analysis

A statistical analysis of the results was performed using the paired t-test, non-paired t-test, or non-parametric test (Wilcoxon's signed rank test). The relationship between each parameter was tested using Pearson's correlation coefficient. A value of $p < 0.05$ was considered to indicate a statistically significant change. Dr.SPSSII, a software program (manufactured by SPSS Inc.) was used in this study.

Results

Test results

Tables 1 and 2 show the physical measurement values. The Test Group showed no significant changes in height, weight, body water content, muscle volume, lean muscle mass, skeletal muscle volume, body fat volume, BMI, body fat percentage, waist-hip ratio, basal metabolism, or blood pressure. The Control Group, on the other hand, showed slightly significant changes in body water content (2.1%, $p = 0.002$), muscle volume (2.0%, $p = 0.002$), lean muscle mass (2.0%, $p = 0.002$) and basal metabolism (1.4%, $p = 0.002$). We compared the rates before and after the test

between the Test and the Control Groups and saw no significant intra-group differences in any of the items.

In the general laboratory tests (Tables 3 and 4), the Test Group showed significant changes in their total cholesterol (4.5%) from 214.0 ± 31.1 to 223.7 ± 31.44 ($p = 0.046$), fasting blood sugar (4.1%) from 91.9 ± 10.6 to 95.7 ± 7.5 ($p = 0.016$), and HbA1c (3.4%) from 4.73 ± 0.43 to 4.89 ± 0.39 ($p = 0.000$). Significant fluctuations were also seen in MCV (1.4%) from 93.5 ± 3.3 to 94.8 ± 3.2 ($p = 0.000$) and MCH (1.3%) from 30.6 ± 1.5 to 31.0 ± 1.4 ($p = 0.000$), but they were slight changes within the range of 1.4%. The Control Group showed significant variations in the leukocyte count (–10.9%) from 7244.0 ± 2665.9 to 6456.7 ± 2120.0 ($p = 0.020$) and HbA1c (2.9%) from 4.89 ± 0.40 to 5.03 ± 0.43 ($p = 0.001$). Although a significant fluctuation was seen in MCV (1.0%) from 92.6 ± 5.6 to 93.5 ± 5.7 ($p = 0.038$), the change was only 1.0%. Intra-group analysis showed no significant differences between the two groups.

The Test Group showed no significant variations in lactic acid, insulin, IGF-I, cortisol, or DHEA-s (Tables 3 and 4). The Control Group, meanwhile, showed a significant variation in IGF-I (–8.8%) from 197.9 ± 68.9 to 180.6 ± 60.4 ($p = 0.007$). An intra-group analysis showed no significant differences between the two groups.

Regarding oxidation stress markers (Tables 3 and 4), the Test Group showed a significant reduction in blood lipid peroxide (–12.8%) from 0.39 ± 0.07 to 0.34 ± 0.08 ($p = 0.001$) but no significant changes in the speed of urinary 8-OHdG formation, or the speed of isoprostane formation, 8-OHdG/CRE, or isoprostane/CRE. The Control Group, on the other hand, showed no significant changes in lipid peroxides, and no significant variations in other urinary markers. An intra-group analysis showed no significant differences between the two groups.

Tables 5–8 show the results of the analysis on the Anti-Aging QOL Common Questionnaire (AAQol). Regarding physical symptoms, the Test Group showed significant improvements in scores of the following 8 out of 30 items: “tired eyes” ($p = 0.015$), “blurry eyes” ($p = 0.035$), “muscle pain/stiffness” ($p = 0.017$), “early satiety” ($p = 0.042$), “epigastralgia” ($p = 0.010$), “dizziness” ($p = 0.003$), “arthralgia” ($p = 0.037$), and “easily breaking into a sweat” ($p = 0.026$). The Control Group did not show improvements in any of the scores. Intra-group analysis showed a significant difference between the two groups in terms of changes in the score for “dizziness” ($p = 0.008$).

As for mental symptoms, the Test Group showed no items (of the 21 items) whose scores had improved. The Control Group showed a significant improvement in the score for a single item: “sleeping disturbance” ($p = 0.019$). An intra-group analysis showed no significant differences between the two groups.

Table 1. Physical measurements of Test Group

	Unit	Before	8 weeks later	<i>P</i> value vs “before” value	<i>P</i> value vs Control Group
Height	kg	163.1 ± 7.9	163.2 ± 7.8	0.348	0.846
Weight	kg/m ²	69.9 ± 7.2	70.1 ± 7.0	0.439	0.964
Total body water	L	33.8 ± 5.9	34.4 ± 5.5	0.083	0.983
Muscle volume	cm	46.2 ± 8.0	47.0 ± 7.5	0.079	0.983
Lean body weight	kg	48.9 ± 8.4	49.8 ± 7.8	0.084	0.984
Skeletal muscle volume	kg	26.4 ± 5.3	26.5 ± 4.9	0.667	0.597
Body fat amount	kg	21.0 ± 3.9	20.5 ± 3.7	0.238	0.977
BMI		26.3 ± 1.7	26.3 ± 1.7	0.643	0.999
Body fat percentage	%	29.8 ± 6.5	29.4 ± 6.0	0.652	0.614
Waist/hip ratio		0.92 ± 0.04	0.91 ± 0.04	0.331	0.797
Basal metabolism	kcal	1315.8 ± 175.2	1331.3 ± 166.9	0.094	0.965
Systolic pressure	mmHg	126.9 ± 12.0	125.9 ± 12.1	0.608	0.665
Diastolic pressure	mmHg	83.4 ± 7.7	81.6 ± 8.2	0.275	0.972

n = 18, mean ± SD, paired *t* test or Mann-Whitney *U* test

Table 2. Physical measurements of Control Group

	Unit	Before	8 weeks later	<i>P</i> value vs “before” value	<i>P</i> value vs Test Group
Height	kg	163.6 ± 11.2	163.5 ± 11.2	0.924	0.846
Weight	kg/m ²	66.5 ± 11.9	66.6 ± 12.2	0.714	0.964
Total body water	L	33.8 ± 7.8	34.5 ± 7.8	0.002	0.983
Muscle volume	cm	46.1 ± 10.6	47.0 ± 10.6	0.002	0.983
Lean body weight	kg	48.8 ± 11.1	49.8 ± 11.1	0.002	0.984
Skeletal muscle volume	kg	26.3 ± 7.2	26.7 ± 7.0	0.062	0.597
Body fat amount	kg	17.6 ± 4.5	17.3 ± 4.8	0.209	0.977
BMI		24.7 ± 2.9	24.7 ± 3.0	0.748	0.999
Body fat percentage	%	27.0 ± 6.5	26.1 ± 6.7	0.082	0.614
Waist/hip ratio		0.89 ± 0.04	0.89 ± 0.04	0.135	0.797
Basal metabolism	kcal	1325.8 ± 243.2	1344.3 ± 243.7	0.002	0.965
Systolic pressure	mmHg	132.3 ± 18.8	126.7 ± 15.8	0.210	0.665
Diastolic pressure	mmHg	86.1 ± 13.8	83.0 ± 13.5	0.316	0.972

n = 17, mean ± SD, paired *t* test or Mann-Whitney *U* test

Variations associated with gender

A factorial correlational analysis was performed by gender and for each item. Results of physical measurements showed higher values in men for height, weight, body water content, muscle volume, lean muscle mass, skeletal muscle volume and basal metabolism. Women had a significantly higher percentage of body fat. Regarding the lifestyles of subjects, men showed a significantly higher use of alcoholic drinks

and cigarettes.

Regarding physical symptoms, slightly more men than women suffered “diarrhea” and “lumbago” ($p < 0.05$), while more women than men suffered “excessive sensitivity to cold” ($p < 0.01$). No gender differences were seen in mental symptoms.

Regarding general laboratory test items, men showed significantly higher values than women in their erythrocyte

Table 3. Clinical tests of Test Group

	Unit	Before	8 weeks later	<i>P</i> value vs “before” value	<i>P</i> value vs Control Group
Leukocyte Count (WBC)	/μl	6051.1 ± 1506.1	6008.9 ± 1717.5	0.841	0.335
Erythrocyte Count (RBC)	10 ⁴ /μl	471.9 ± 33.6	471.9 ± 41.6		0.865
Hemoglobin Content (HGB)	g/dl	14.5 ± 1.3	14.6 ± 1.4	0.149	0.497
Hematocrit (HCT)	%	44.1 ± 3.3	44.7 ± 3.9	0.183	0.741
Mean Corpuscular Volume (MCV)	fl	93.5 ± 3.3	94.8 ± 3.2	0.000	0.736
Mean Corpuscular Hemoglobin (MCH)	pg	30.6 ± 1.5	31.0 ± 1.4	0.000	0.270
Mean Corpuscular Hemoglobin Concentration (MCHC)	%	32.7 ± 0.9	32.7 ± 0.9		0.568
Platelet count	10 ⁴ /μl	22.5 ± 3.3	22.9 ± 4.1	0.470	0.867
Glutamate Oxaloacetate Transaminase (GOT)	U/l	24.6 ± 11.5	23.7 ± 9.9	0.368	0.974
Glutamate Pyruvate Transaminase (GPT)	U/l	32.2 ± 30.2	30.2 ± 25.4	0.401	0.992
Alkaline phosphatase (ALP)	IU/l	238.7 ± 66.5	227.4 ± 56.6	0.161	0.889
γ-glutamyl transpeptidase (γ-GTP)	IU/l	59.3 ± 49.8	54.2 ± 47.1	0.236	0.790
Blood Creatinine (Cr)	mg/dl	0.68 ± 0.12	0.69 ± 0.13	0.300	0.962
Blood Urea Nitrogen (BUN)	mg/dl	13.4 ± 2.8	12.7 ± 2.5	0.274	0.587
Uric acid (UA)	mg/dl	5.69 ± 1.42	5.51 ± 1.26	0.235	0.570
Creatine Phosphokinase (CPK)	mU/ml	126.4 ± 58.1	123.9 ± 76.6	0.826	0.429
Total cholesterol	mg/dl	214.0 ± 31.1	223.7 ± 31.4	0.046	0.887
HDL-cholesterol	mg/dl	52.8 ± 12.4	54.4 ± 12.7	0.182	0.525
LDL-cholesterol	mg/dl	135.7 ± 29.9	142.3 ± 26.8	0.091	0.691
Triglycerides (TG)	mg/dl	144.0 ± 78.1	136.9 ± 68.8	0.546	0.905
Na	mEq/l	142.8 ± 1.5	143.2 ± 1.1	0.130	0.983
K	mEq/l	4.19 ± 0.37	4.16 ± 0.28	0.622	0.882
Cl	mEq/l	104.9 ± 2.1	104.8 ± 1.7	0.915	0.905
Fasting Blood Sugar (FBS)	mg/dl	91.9 ± 10.6	95.7 ± 7.5	0.016	0.615
Glycohemoglobin A1C (HbA1c)	%	4.73 ± 0.43	4.89 ± 0.39	0.000	0.799
C-Reactive Protein (CRP)	mg/dl	0.22 ± 0.15	0.21 ± 0.14	0.870	0.685
Lactic acid	mg/dl	9.54 ± 5.83	8.52 ± 3.17	0.279	0.471
Lipid peroxide (LPO)	nmol/ml	0.39 ± 0.07	0.34 ± 0.08	0.001	0.802
Insulin	μU/ml	7.56 ± 4.12	8.33 ± 3.87	0.364	0.648
IGF-I	ng/ml	185.3 ± 42.9	175.1 ± 31.3	0.160	0.636
Cortisol	μg/dl	11.4 ± 5.0	9.4 ± 4.0	0.071	0.562
Dehydroepiandrosterone Sulfate (DHEA-s)	ng/ml	1600.1 ± 792.2	1589.1 ± 979.9	0.928	0.993
8-hydroxy-deoxyguanosine (8-OHdG) generation	ng/kg/hr	8.78 ± 5.2	7.46 ± 4.63	0.186	0.549
Isoprostane generation	ng/kg/hr	145.2 ± 73.8	114.4 ± 69.6	0.060	0.427
8-OHdG/CRE	ng/mgCRE	126.0 ± 65.3	126.5 ± 90.2	0.488	0.353
Isoprostane/CRE	ng/mgCRE	1977.2 ± 848.0	1631.5 ± 635.9	0.054	0.338

n = 18, mean ± SD, paired *t* test or Mann-Whitney *U* test

Table 4. Clinical tests of Control Group

	Unit	Before	8 weeks later	<i>P</i> value vs “before” value	<i>P</i> value vs Test Group
Leukocyte Count (WBC)	/μl	7244.0 ± 2665.9	6456.7 ± 2120.0	0.020	0.335
Erythrocyte Count (RBC)	10 ⁴ /μl	468.6 ± 40.0	464.7 ± 42.0	0.477	0.865
Hemoglobin Content (HGB)	g/dl	14.2 ± 1.6	14.2 ± 1.7	0.768	0.497
Hematocrit (HCT)	%	43.3 ± 3.7	43.4 ± 3.8	0.863	0.741
Mean Corpuscular Volume (MCV)	fl	92.6 ± 5.6	93.5 ± 5.7	0.038	0.736
Mean Corpuscular Hemoglobin (MCH)	pg	30.4 ± 2.6	30.5 ± 2.7	0.293	0.270
Mean Corpuscular Hemoglobin Concentration (MCHC)	%	32.8 ± 1.3	32.6 ± 1.3	0.309	0.568
Platelet count	10 ⁴ /μl	26.4 ± 4.5	26.5 ± 5.6	0.810	0.867
Glutamate Oxaloacetate Transaminase (GOT)	U/l	23.4 ± 5.3	22.3 ± 5.5	0.408	0.974
Glutamate Pyruvate Transaminase (GPT)	U/l	27.3 ± 11.3	26.3 ± 11.0	0.618	0.992
Alkaline phosphatase (ALP)	U/l	251.3 ± 71.2	244.0 ± 63.8	0.443	0.889
γ-glutamyl transpeptidase (γ-GTP)	U/l	49.1 ± 40.2	50.7 ± 47.7	0.736	0.790
Blood Creatinine (Cr)	mg/dl	0.68 ± 0.15	0.69 ± 0.15	0.241	0.962
Blood Urea Nitrogen (BUN)	mg/dl	14.3 ± 3.7	14.2 ± 2.6	0.923	0.587
Uric acid (UA)	mg/dl	5.59 ± 1.26	5.64 ± 1.14	0.799	0.570
Creatine Phosphokinase (CPK)	mg/dl	138.6 ± 91.0	183.9 ± 251.4	0.327	0.429
Total cholesterol	mg/dl	224.6 ± 47.2	230.5 ± 50.8	0.346	0.887
HDL-cholesterol	mg/dl	51.5 ± 7.8	55.6 ± 11.2	0.069	0.525
LDL-cholesterol	mg/dl	147.6 ± 46.3	148.1 ± 43.7	0.910	0.691
Triglycerides (TG)	mg/dl	173.4 ± 147.7	132.3 ± 57.7	0.259	0.905
Na	mEq/l	142.4 ± 1.2	142.9 ± 1.2	0.150	0.983
K	mEq/l	4.21 ± 0.30	4.13 ± 0.26	0.395	0.882
Cl	mEq/l	104.1 ± 1.6	104.4 ± 2.0	0.658	0.905
Fasting Blood Sugar (FBS)	mg/dl	92.9 ± 9.4	94.3 ± 10.3	0.576	0.615
Glycohemoglobin A1C (HbA1c)	%	4.89 ± 0.40	5.03 ± 0.43	0.001	0.799
C-Reactive Protein (CRP)	mg/dl	0.19 ± 0.10	0.17 ± 0.11	0.262	0.685
Lactic acid	mg/dl	8.17 ± 3.45	9.56 ± 3.51	0.173	0.471
Lipid peroxide (LPO)	nmol/ml	0.65 ± 0.99	0.32 ± 0.08	0.216	0.802
Insulin	μU/ml	9.00 ± 7.13	7.93 ± 3.83	0.543	0.648
IGF-I	ng/ml	197.9 ± 68.9	180.6 ± 60.4	0.007	0.636
Cortisol	μg/dl	9.9 ± 3.0	10.2 ± 6.8	0.873	0.562
Dehydroepiandrosterone Sulfate (DHEA-s)	ng/ml	2034.1 ± 1136.3	1928.3 ± 899.5	0.474	0.993
8-hydroxy-deoxyguanosine (8-OHdG) generation	ng/kg/hr	9.45 ± 7.41	8.85 ± 4.59	0.282	0.549
Isoprostane generation	ng/kg/hr	142.2 ± 88.7	138.1 ± 85.5	0.336	0.427
8-OHdG/CRE	ng/mgCRE	116.0 ± 73.9	128.5 ± 71.7	0.233	0.353
Isoprostane/CRE	ng/mgCRE	1846.1 ± 869.6	1837.8 ± 1117.4	0.377	0.338

n = 17, mean ± SD, paired *t* test or Mann-Whitney *U* test

Table 5. Physical symptoms of Test Group

	Before	8 weeks later	<i>P</i> value vs “before” value	<i>P</i> value vs Control Group
Tired eyes	3.1 ± 1.0	2.6 ± 1.0	0.015	0.826
Blurry eyes	2.5 ± 0.9	2.0 ± 1.0	0.035	0.122
Eye pain	1.9 ± 0.9	1.6 ± 0.8	0.135	0.360
Stiff shoulders	3.6 ± 1.2	3.2 ± 1.3	0.138	0.992
Muscle pain/stiffness	3.4 ± 1.3	2.8 ± 1.3	0.017	0.277
Palpitations	1.7 ± 0.8	1.7 ± 0.8	0.579	0.692
Dyspnea	1.9 ± 0.9	1.7 ± 0.8	0.135	0.171
Tendency to gain weight	3.9 ± 0.9	3.7 ± 0.9	0.361	0.861
Weight loss; thin	1.2 ± 0.4	1.1 ± 0.3	0.331	0.343
Lethargy	2.9 ± 1.0	2.4 ± 1.0	0.134	0.403
No feeling of good health	2.3 ± 1.0	2.2 ± 0.9	0.528	0.655
Thirst	1.9 ± 0.8	1.9 ± 1.0		0.895
Skin problems	2.3 ± 1.3	2.3 ± 1.2		0.728
Anorexia	1.7 ± 0.8	1.5 ± 0.8	0.331	0.988
Early satiety	1.9 ± 0.9	1.5 ± 0.9	0.042	0.314
Epigastralgia	1.8 ± 0.8	1.4 ± 0.7	0.010	0.293
Liable to catch colds	2.0 ± 1.0	2.1 ± 1.0	0.842	0.977
Coughing and sputum	2.2 ± 1.1	2.3 ± 1.1	0.528	
Diarrhea	2.1 ± 0.6	2.0 ± 0.9	0.772	0.432
Constipation	2.2 ± 1.2	2.2 ± 1.2	0.749	0.998
Headache	2.1 ± 0.8	2.2 ± 0.9	0.790	0.624
Dizziness	1.8 ± 0.7	1.3 ± 0.5	0.003	0.008
Tinnitus	1.9 ± 0.8	1.7 ± 1.0	0.104	0.086
Lumbago	3.2 ± 1.2	2.7 ± 1.0	0.088	0.353
Arthralgia	2.7 ± 1.0	2.2 ± 0.8	0.037	0.257
Edematous	2.6 ± 1.2	2.6 ± 1.1		0.908
Easily beaking into a sweat	3.8 ± 1.1	3.0 ± 1.3	0.026	0.310
Frequent urination	2.4 ± 1.1	2.4 ± 1.3	0.859	0.727
Hot flashes	1.9 ± 1.0	1.8 ± 1.0	0.834	0.992
Excessive sensitivity to cold	2.1 ± 1.0	2.3 ± 1.1	0.260	0.944

n = 18, mean ± SD, paired *t* test or Mann-Whitney *U* test

count, hemoglobin content, hematocrit, GPT, γ -GTP, creatinine, and uric acid levels. Special tests such as hormone levels showed that men had significantly higher values than women in terms of cortisol ($p < 0.05$) and DHEA-s ($p < 0.05$). In oxidation stress marker tests, men showed a significantly higher 8-OHdG/CRE value than did the women. However, none of the other items showed any gender differences. Improvement rates of oxidation stress markers before and after the tests showed no gender differences.

Variations associated with aging

A correlational analysis was performed between chronological age and each test item. Regarding the results of physical measurement, height, weight, body water content and muscle volume, lean muscle mass, skeletal muscle volume and basal metabolism, they were lower with advanced age ($p < 0.01$), while body fat percentage and waist/hip ratio was higher with respect to age ($p < 0.05$). Regarding general laboratory test items, those that rose with age were creatinine ($p < 0.01$), uric acid ($p < 0.05$) and HDL-C

Table 6. Physical symptoms of Control Group

	Before	8 weeks later	<i>P</i> value vs “before” value	<i>P</i> value vs Test Group
Tired eyes	2.7 ± 0.8	2.5 ± 1.1	0.582	0.826
Blurry eyes	2.1 ± 0.9	2.2 ± 0.9	0.610	0.122
Eye pain	1.7 ± 0.7	1.8 ± 0.9	0.582	0.360
Stiff shoulders	3.6 ± 0.9	3.3 ± 0.9	0.217	0.992
Muscle pain/stiffness	2.7 ± 1.3	2.5 ± 1.0	0.424	0.277
Palpitations	1.7 ± 0.8	1.7 ± 0.9		0.692
Dyspnea	1.8 ± 0.9	1.9 ± 0.9	0.634	0.171
Tendency to gain weight	3.2 ± 1.1	3.1 ± 0.9	0.499	0.861
Weight loss; thin	1.5 ± 0.6	1.6 ± 0.5	0.334	0.343
Lethargy	2.5 ± 1.2	2.6 ± 1.1	0.774	0.403
No feeling of good health	2.5 ± 0.9	2.1 ± 1.1	0.207	0.655
Thirst	2.1 ± 1.1	2.0 ± 0.8	0.634	0.895
Skin problems	2.4 ± 1.1	2.4 ± 1.5		0.728
Anorexia	1.8 ± 0.6	1.7 ± 0.5	0.164	0.988
Early satiety	1.9 ± 0.8	2.0 ± 0.8	0.433	0.314
Epigastralgia	1.8 ± 0.9	1.8 ± 0.7		0.293
Liable to catch colds	1.9 ± 0.9	1.9 ± 0.7	0.751	0.977
Coughing and sputum	1.9 ± 0.9	2.1 ± 0.7	0.104	
Diarrhea	2.1 ± 0.9	2.2 ± 0.8	0.610	0.432
Constipation	2.1 ± 1.2	2.0 ± 1.0	0.670	0.998
Headache	2.3 ± 1.3	2.1 ± 1.0	0.262	0.624
Dizziness	1.5 ± 0.9	1.7 ± 0.7	0.104	0.008
Tinnitus	1.6 ± 0.9	1.8 ± 0.9	0.189	0.086
Lumbago	2.7 ± 1.6	2.7 ± 1.2	0.774	0.353
Arthralgia	2.0 ± 1.2	2.1 ± 1.0	0.865	0.257
Edematous	2.3 ± 1.0	2.2 ± 0.7	0.818	0.908
Easily breaking into a sweat	2.8 ± 1.3	2.7 ± 1.1	0.653	0.310
Frequent urination	1.7 ± 0.9	1.8 ± 0.7	0.774	0.727
Hot flashes	1.9 ± 0.9	1.8 ± 0.6	0.546	0.992
Excessive sensitivity to cold	2.0 ± 1.3	2.3 ± 1.0	0.217	0.944

n = 17, mean ± SD, paired *t* test or Mann-Whitney *U* test

(*p*<0.05), but HbA1c decreased with age (*p*<0.01). Tests for hormones showed that DHEA-s decreased with age (*p*<0.01). As for oxidation stress markers, the volume of 8-OHdG production decreased with age (*p*<0.05), as did 8-OHdG/CRE (*p*<0.01), while the improvement rates of 8-OHdG/CRE dropped with age (*p*<0.05). Of the Anti-Aging QOL Common Questionnaire (AAQoL) items, among physical symptoms, scores for “anorexia” and “excessive sensitivity to cold” increased with age (*p*<0.05). Regarding mental symptoms, the score for “shallow sleep” increased

with age (*p*<0.05).

Variations between test items

Items in which the Test Group showed significant changes before and after the test, namely, total cholesterol, fasting blood sugar, HbA1c, lipid peroxide, “tired eyes,” “blurry eyes,” “muscle pain/stiffness,” “early satiety,” “epigastric pain,” “dizziness,” “arthralgia” and “easily breaking into a sweat,” we studied the factors that influenced the change rates. Total cholesterol’s degree of change increased in

Table 7. Mental symptoms of Test Group

	Before	8 weeks later	<i>P</i> value vs “before” value	<i>P</i> value vs Control Group
Irritability	2.7 ± 0.8	2.6 ± 1.1	0.651	0.348
Easily angered/short-tempered	2.6 ± 0.9	2.5 ± 1.1	0.651	0.131
Loss of motivation	2.6 ± 1.1	2.1 ± 1.1	0.058	0.985
No feeling of happiness	2.0 ± 1.0	2.0 ± 1.1		0.983
Nothing to look forward to in life	2.0 ± 1.2	1.8 ± 0.9	0.386	0.926
Daily life is not enjoyable	2.1 ± 1.0	2.0 ± 0.9	0.717	0.800
Lose of confidence	1.7 ± 0.8	1.7 ± 0.9	0.749	0.911
Reluctance to talk with others	2.2 ± 0.9	1.7 ± 0.8	0.057	0.573
Depressed	2.0 ± 0.9	1.9 ± 1.0	0.542	0.909
A feeling of uselessness	1.8 ± 0.7	1.8 ± 0.9		0.831
Shallow sleep	2.2 ± 0.9	2.1 ± 1.2	0.528	0.998
Difficulty falling asleep	1.8 ± 0.9	1.7 ± 0.8	0.269	0.708
Pessimism	2.3 ± 0.8	2.2 ± 1.0	0.421	0.834
Lapse of memory	2.9 ± 0.9	2.8 ± 1.2	0.430	0.706
Inability to concentrate	2.3 ± 1.2	2.3 ± 1.0	0.790	0.849
Inability to solve problems	2.1 ± 1.1	1.9 ± 1.0	0.163	0.499
Inability to make judgements readily	2.1 ± 1.0	1.9 ± 1.0	0.163	0.315
Inability to sleep because of worries	1.7 ± 0.7	1.9 ± 1.0	0.331	0.214
A sense of tension	2.1 ± 0.9	2.4 ± 0.9	0.083	0.065
Feeling of anxiety for no special reason	1.6 ± 0.6	1.6 ± 0.5	0.717	0.772
Vague feeling of fear	1.6 ± 0.7	1.7 ± 0.6	0.772	0.842

n = 18, mean ± SD, paired *t* test or Mann-Whitney *U* test

correlation to the number of cigarettes smoked ($r = 0.37$, $p < 0.05$). The lower the insulin values ($r = -0.50$, $p < 0.01$) and 8-OHdG/CRE values ($r = -0.36$, $p < 0.01$), the higher the degree of change of fasting blood sugar. Women showed a high increase rate of HbA1c ($p < 0.05$). The degree of change in lipid peroxides tended to decrease in women ($p < 0.01$), in young people ($r = -0.37$, $p < 0.01$), in those with a high alcohol consumption ($p < 0.05$), in those with high cortisol levels ($r = -0.35$, $p < 0.05$), and in those with high values for height, body water content, muscle volume, lean muscle mass, skeletal muscle volume, and body fat, as well as those with high blood pressure ($r = 0.46$, $p < 0.05$).

The improvement in scores for “tired eyes” was most marked in subjects with high cortisol values ($r = -0.38$, $p < 0.05$), and in subjects who were extremely “irritable” ($r = -0.38$, $p < 0.05$) or “easily angered/short-tempered” ($r = -0.35$, $p < 0.05$). The degree of change in scores for “blurry eyes” was most marked in subjects with low insulin

levels ($r = 0.36$, $p < 0.05$) and low diastolic pressure ($r = 0.37$, $p < 0.05$). The improvement in scores for “muscle pain/stiffness” was most marked in younger subjects ($r = 0.44$, $p < 0.05$), but less so for subjects with “shallow sleep” ($r = 0.43$, $p < 0.05$). Scores for “early satiety” ($r = 0.42$, $p < 0.05$) and “epigastric pain” ($r = 0.51$, $p < 0.01$) tended to improve less readily in subjects with “shallow sleep.” There were no factors that affected the improvement rates in the score for “dizziness.” The improvement in score for “arthralgia” was most marked in heavy smokers ($r = -0.36$, $p < 0.05$), subjects who were “irritable” ($r = -0.39$, $p < 0.05$), “easily angered/short-tempered” ($r = -0.35$, $p < 0.05$), or “depressed” ($r = -0.38$, $p < 0.05$). The scores tended to improve less in those who engaged in regular and vigorous exercise ($r = 0.53$, $p < 0.05$). The degree of improvement in the scores for “easily breaking into a sweat” tended to be low in subjects with high cortisol values ($r = -0.36$, $p < 0.05$), but was higher in subjects who had a “loss of motivation”

Table 8. Mental symptoms of Control Group

	Before	8 weeks later	<i>P</i> value vs “before” value	<i>P</i> value vs Test Group
Irritability	2.3 ± 1.0	2.5 ± 0.6	0.433	0.348
Easily angered/short-tempered	2.3 ± 1.1	2.5 ± 0.6	0.384	0.131
Loss of motivation	2.3 ± 0.8	2.0 ± 0.7	0.055	0.985
No feeling of happiness	2.2 ± 0.8	2.1 ± 0.7	0.774	0.983
Nothing to look forward to in life	2.1 ± 0.9	1.9 ± 0.5	0.499	0.926
Daily life is not enjoyable	2.3 ± 0.8	2.0 ± 0.5	0.217	0.800
Lose of confidence	2.3 ± 0.8	1.9 ± 0.5	0.173	0.911
Reluctance to talk with others	1.9 ± 0.8	1.9 ± 0.7		0.573
Depressed	2.1 ± 0.8	2.1 ± 0.7	0.774	0.909
A feeling of uselessness	2.1 ± 0.5	2.1 ± 0.5		0.831
Shallow sleep	2.5 ± 1.1	2.3 ± 0.9	0.189	0.998
Difficulty falling asleep	2.3 ± 1.0	1.9 ± 0.7	0.019	0.708
Pessimism	2.6 ± 1.0	2.2 ± 0.7	0.054	0.834
Lapse of memory	2.9 ± 0.7	2.9 ± 0.6		0.706
Inability to concentrate	2.2 ± 0.7	2.3 ± 0.6	0.582	0.849
Inability to solve problems	2.1 ± 0.5	2.2 ± 0.7	0.334	0.499
Inability to make judgements readily	2.2 ± 0.8	2.3 ± 0.6	0.774	0.315
Inability to sleep because of worries	2.4 ± 1.0	2.1 ± 0.8	0.136	0.214
A sense of tension	2.4 ± 0.6	2.3 ± 0.7	0.433	0.065
Feeling of anxiety for no special reason	1.9 ± 0.9	1.8 ± 0.6	0.499	0.772
Vague feeling of fear	1.7 ± 0.6	1.7 ± 0.7		0.842

n = 17, mean ± SD, paired *t* test or Mann-Whitney *U* test

(*r* = 0.41, *p* < 0.05).

Discussion

Amino acids

A healthy individual with a standard weight of 60 kg is said to require about 2,000 to 2,400 kcal per day, with the ratio among carbohydrates, protein and fat ideally being 6:2:2. The ideal daily protein intake, moreover, is said to be within the range of 80 to 120 g. We await more investigations on the optimal doses based on EBM. It is recommended that between 5 and 10 g of amino acids be replenished in the form of amino acid supplements if individuals fail to meet the required protein intake level due to eating irregularly, or if their masticatory capabilities have weakened [1].

In the course of protein being synthesized from amino acids *in vivo*, it requires the aid of vitamin B₆ and other

substances. Antioxidants such as vitamin C and E are also useful in suppressing the free radicals that develop during this process.

The human body is composed of 20 types of amino acids. There are ten amino acids that cannot be synthesized *in vivo* and therefore must be obtainable from food: valine, leucine, isoleucine, histidine, phenylalanine, tryptophan, lysine, methionine, arginine, and threonine. There are ten nonessential amino acids that can be synthesized *in vivo*: glutamine, proline, glycine, asparagine, glutamic acid, aspartic acid, cysteine, tyrosine, serine, and alanine.

The synthetic capability *in vivo* of nonessential amino acids generally declines with age. What is especially important is not chronological age, but hormonal age, as revealed in a reduction in DHEA, growth hormones and IGF-I. Growth hormones and IGF-I directly affect amino acid synthesis, and decreased DHEA that is synthesized in the adrenal gland indirectly affects the synthesis of amino acids

and proteins via reductions in protein-synthesizing hormones that are synthesized based on DHEA and in androgens that have protein anabolic activity.

Carnitine

Carnitine is a type of amino acid. L-carnitine works to combine with acyl-CoA that is generated intracellularly from free fatty cells to produce acylcarnitine and to enable the passage of acyl-CoA through endosporium of mitochondria [8–13]. Therefore, it is essential to the metabolism of intracellular fat; it also works to reduce the dependence of the body on sugar as a source of energy. It protects against degeneration of nerve cells, so it is believed to be useful for preventing loss of short-term memory, Alzheimer's disease, and depression [11]. There are also reports that carnitine helps in the treatment of liver and heart diseases [13], of male reproductive functions and mental stress [10] and in restoring visual acuity. It also has the potential to reduce the levels of lipids circulating within the blood and thus lower the risk of arteriosclerosis [13]. Deficiency in carnitine induces impaired intracellular fat metabolism [8]. Foods that contain abundant carnitine include mutton and beef.

A study that measured the amount of carnitine in the plasma and the liver of 68 pediatric chronic liver disease and 36 cirrhosis patients showed that the latter patients had low plasma carnitine concentrations [14]. Meanwhile, in a study using 382 hyperlipidemia patients taking statin drugs (167 males and 215 females; mean age: 63.17 years), patients given oral statins had higher CPK levels than normal populations, and had significantly lower plasma acylcarnitine levels. This suggests the possibility that, for some unknown reason, individuals on oral statin drugs have fatty acid metabolic abnormalities due to abnormal carnitine metabolism, and that this may be one of the causes of the rise in CPK levels and myopathy [15].

Carnitine in animal models

Carnitine influences metabolic mechanisms in numerous ways. A study in which 200 mg/kg of L-carnitine was administered for 4 weeks to streptomycin-induced diabetic rats showed that the drug helped to restore serum IGF-I to close to normal concentrations [16]. In septic rats that had undergone appendix ligation and perforation, the concentration of endotoxins in the blood rose, while the concentrations of branched chain amino acids in the blood (leucine, isoleucine and valine) as well as glutamine were lower. Administration of L-carnitine, however, is shown to suppress declines in the concentrations of branched-chain amino acids and glutamine [17]. Aged rats, in particular, show decreases in the content of protein in each tissue as well as the level of protein-bound hexose, hexosamine, sialic acid, and fucose. However, intra-abdominal administration of L-carnitine is shown to improve the conditions of these

glycoproteins. On the other hand, in young rats, the administration of L-carnitine does not induce these changes, suggesting that carnitine helps in normalizing age-induced changes in glycoproteins [18].

Carnitine also affects the gastrointestinal tract. There is a reduction in gastric mucins and prostaglandin E₂ of rats subjected to cold stress. However, the administration of L-carnitine suppresses this reduction as well as the development of gastric mucosal lesions and formation of lipid peroxide. Administration of L-carnitine is also shown to elevate catalase activity in the blood and inside the gastric mucosal membrane [19].

Carnitine also acts on the sensory organs. In a study in which palmitoyl-DL-carnitine (1×10^{-4} M) was administered to guinea pigs via perilymphatic reflux, measurements of the endocochlear DC potential and cochlear microphonics showed the former to have dropped to $+8 \sim +16$ mV, and the latter to 30 ~ 39%, suggesting a direct effect of palmitoyl-DL-carnitine on cochlear hair cells [20].

Several reports have been published on the effects of carnitine on the heart. Administration of adriamycin reduces free carnitine in rat cardiac muscle and boosts acylcarnitine levels. These, however, were shown to improve after 500 mg/kg of L-carnitine was administered intra-abdominally on a daily basis, showing that L-carnitine counteracts cardiotoxicity of adriamycin [21]. In a study using rat models of ischemic myocardial disorders, administration of L-carnitine prior to re-reflux was shown to increase free carnitine, activating fatty acid metabolism after re-reflux and improving glycolytic metabolism that was impaired because of ischemia, thereby improving myocardial metabolism and promoting the recovery of myocardial function [22]. In another study that investigated the effects of L-carnitine in which extracted reflux heart of diabetic rats (a state of diabetic cardiac dysfunction such as reduction in systolic and diastolic functions) was used, reduced intra-myocardial carnitine content was seen to improve with oral administration of propionyl-L-carnitine. The drug also increased intra-myocardial carnitine and improved cardiac function [23].

Clinical effects of carnitine

Initially, reports on the activity of carnitine in humans mostly focused on cardiac function. In a study in which 200 mg/day of L-carnitine was administered to nine patients with heart disease (i.e., history of myocardial infarction) after undergoing ergometer exercise tests, the subjects showed improvements in exercise time peak value and maximum oxygen consumption volume, as well as higher lactic acid and ventilation thresholds. L-carnitine was therefore shown to improve loss of exercise tolerance [24]. In a study in which L-carnitine was administered orally for 12 weeks, exercise tolerance significantly improved in exer-

tional angina patients, while 5 out of 9 chronic congestive heart failure patients were switched to a less severe NYHA class category, and 6 patients saw their systemic conditions improve [25]. In a study in which 60 mg/kg of levocarnitine was administered via intravenous drip to 15 ischemic heart disease patients, myocardial metabolism and blood flow increase during exercise were stepped up, indicating that the drug demonstrated anti-angina activity [26]. In a study that compared the effects of levocarnitine chloride and a placebo in 46 stable, exertional angina patients, administration of levocarnitine was shown to extend the time of exercise in multiple-stage treadmill exercise tests and prolong the time to onset of angina pain [27]. Meanwhile, a multi-center, double-blind, placebo-controlled intra-group comparative test was performed, targeting 114 angina patients who still suffered angina pain despite administration of timed-released nitric acid drugs. A combination of timed-released nitric acid drugs and levocarnitine chloride was used. As a result, compared with the Control Group, the Levocarnitine Group saw significant improvements in their exercise ECG [28]. Levocarnitine preparations are used today as L-Cartin®, a drug covered by Japanese health insurance.

There are also reports on the use of L-carnitine as a dietary supplement for patients with renal failure. In a study of 17 hemodialysis patients who were undergoing continuous maintenance therapy comprising erythropoietin, the maintenance dosage of erythropoietin correlated negatively to serum free carnitine concentration. Twenty weeks after taking 500 mg/day of carnitine chloride, four patients saw an over 20% improvement in their hematocrit values, three of whom were able to reduce the dose of erythropoietin [29]. In a study targeting 7 chronic renal failure patients undergoing hemodialysis (mean: 61 ± 17 years, mean history of dialysis: 17 ± 10 years), as a result of administration of L-carnitine (1,000 mg/day for the first month and 500 mg/1–2 days after the second month; the drug was continued for 2 or more years), serum total carnitine concentration improved, the dose of erythropoietin could be decreased, and palpitations as well as post-dialysis fatigue and lethargy improved. These results suggest that dietary supplementation with L-carnitine is useful for improving the QOL of dialysis patients [30].

Recently, reports related to supplements containing carnitine have also been published. In an open test in which ten healthy individuals (4 males; mean age, 40.0 ± 4.2 years; BMI, 27.2 ± 2.2 ; 6 females; mean age, 35.2 ± 9.4 years; BMI, 26.9 ± 2.8) took Metabolic L-Carnitine Plus® for 40 days, both men and women saw a significant reduction in weight, BMI, body fat percentage, bust, waist, hip, upper arm, thigh, and calf circumference; a significant rise in total carnitine, free carnitine, and acylcarnitine; and a significant drop in total cholesterol, triglycerides, blood sugar and lactic acid. The results show the potential usefulness of supple-

ments containing carnitine in promoting lipolysis and energy production in obese individuals [31].

Garcinia cambogia extract

Hydroxycitric acid is a major acid component of the tropical plants *Garcinia cambogia* [32]. (2S, 3S)-HCA from *G. cambogia* was shown to be a potent inhibitor of ATP citrate lyase, which catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA. HCA used in dietary weight loss supplement. In the present study, 500 mg/day of hydroxycitric acid had no significant effect on the body component. The dietary efficacy was not indicated.

Results of our tests

Results of the analysis of the Common Questionnaire (AAQoL) showed that the Test Group revealed significant improvements in a number of physical symptoms. This is believed to be attributable to the comprehensive actions of amino acids and multiple vitamins contained in the Product. Improvement effects on “dizziness,” in particular, showed significant differences between the Test Group and the Control Group, indicating that the Product significantly improved “dizziness.” This is also believed to be related to the direct activity of carnitine on cochlear hair cells [20]. Among the Test Group, symptoms such as “early satiety” and “epigastric pain” improved significantly. Carnitine is known to improve digestive tract movements and to suppress lesions in the gastric mucosal membrane [19], so it is believed to be involved in improving both “early satiety” and “epigastric pain.”

Regarding ocular symptoms, a number of reports have been released. One states that there was a reduction in carnitine inside the ocular lens of diabetic rats [33], while another found carnitine to be effective for ischemic re-reflux disorder in the retina of guinea pigs [34]. There is also a report of a clinical test with human subjects that showed a supplement containing carnitine to counter macular degeneration [35]. The fact that ocular symptoms such as “tired eyes” and “blurry eyes” significantly improved in the Test Group may be attributable to this recovery of the concentration of carnitine in the ocular tissue.

In our laboratory tests, a significant rise was seen in total cholesterol, fasting blood sugar, and HbA1c. Although past reports have shown that carnitine corrects lipid and sugar metabolism [8, 10, 13], our test produced a different result, showing that “early satiety” and “epigastric pain” were alleviated, so it is highly likely that other elements may have come into play, such as increased appetite and improved caloric intake from food. As for oxidation stress markers, lipid peroxides decreased significantly in the Test Group. Carnitine plays an important role in lipid metabolism [8] and possesses anti-oxidation activity [19, 22, 34, 36], so a

decrease in lipid peroxides is not contradictory.

These findings suggest that the consumption of the supplement can reduce the oxidative damage and some symptoms in the human; however, the effect on QOL was equivocal from the results of the effect on lipid metabolism. *Garcinia cambogia* extract did not show dietary efficacy.

Muscular fatigue

If a person undergoes muscular load training for 15 minutes, lactic acid is produced in the muscular tissues; 30 minutes later, growth hormone-reactive secretion peaks from the pituitary gland. Two hours after the start of exercise, fat breaks down, and the concentration of free fatty acid in the blood peaks [2]. In individuals engaging in aerobic exercises such as jogging and aerobics, glucose and fatty acids enter the TCA circuit, which is one of the body's energy-producing systems, to generate energy. In contrast, in anaerobic exercises, such as weightlifting, lactic acid is generated without having glucose and fatty acids enter the TCA circuit. Although lactic acid is a factor that encourages the secretion stimulation of growth hormones, it can also cause muscular pain and fatigue.

In our test, scores for "muscle pain/stiffness" changed from 3.4 ± 1.3 to 2.8 ± 1.3 (-17.6% , $p = 0.017$) in the Test Group, and from 2.7 ± 1.3 to 2.5 ± 1.0 (-7.4%) in the Control Group, showing no significant differences in the improvement rate between the two groups. However, it improved significantly in the Test Group only. An important activity of carnitine is that it combines with acyl-CoA, which is produced from free fatty acids inside the cells, to enable the passage of acyl-CoA through the mitochondrial endosporium [8–13]. This is most likely because, even in muscle cells, which are packed with mitochondria, replenishing carnitine improves the status of metabolism to bring about favorable effects.

Correlations between test items

Administration of the Product induced significant changes in total cholesterol, fasting blood sugar, HbA1c, and lipid peroxide, as well as symptoms such as "tired eyes," "blurry eyes," "muscle pain/stiffness," "early satiety," "epigastric pain," "dizziness," "arthralgia," and "easily breaking into a sweat."

The fact that total cholesterol increases in proportion to the number of cigarettes smoked implies that total cholesterol and smoking, which are risk factors for arteriosclerosis, may work synergistically. This reconfirms the importance of reducing these risk factors one by one to prevent diseases related to arteriosclerosis such as cerebral apoplexy and heart disease. We were not able to identify the relationship between the degree of change in fasting blood sugar and insulin values and 8-OHdG/CRE.

Lipid peroxides are believed to be relatively high in

women who have high body fat percentages, in young people who drink heavily, and in individuals with high values for height, body water content, muscle volume, lean muscle mass, and skeletal muscle volume; these values are liable to drop because of antioxidative substances contained in the Product. It appears, however, that elderly individuals do not demonstrate antioxidative effects very readily. The relationship with cortisol is not clear.

Individuals who have high cortisol values, and who show extreme "irritability" or who are "easily angered/short-tempered" are believed to suffer extensive "tired eyes." It may be that it was relatively easy to see their symptoms related to "tired eyes" improve because of the Product. The causal relationship between the degree of change in the scores for "blurry eyes," insulin value and diastolic blood pressure is not clear. It appears that the older the individual, the more difficult for his or her "muscle pain/stiffness" to improve; the more a person suffers "shallow sleep," the more difficult for it to improve because of insufficient tissue restoration during sleep. It appears that symptoms of "early satiety" and "epigastralgia" are difficult to improve in individuals who often experience "shallow sleep." This suggests the importance of sleep. Heavy smokers and people who have major symptoms of "irritability," "easily angered/short-tempered," and being depressed tend to manifest symptoms of "arthralgia" more strongly than others, so it may be that these symptoms tend to improve more readily as a result of using the Product. People who exercise extensively to begin with have their "arthralgia" already in a steady state, so it may be that their symptoms do not change very readily, even as a result of using the Product. We were unable to identify any relationship between "easily breaking into a sweat" and cortisol value or "loss of motivation."

Acknowledgement

Research for the project was supported by Antiaging Bank Inc. Tokyo, Japan (www.yonei-labo.com), Gingakobo Inc., Nagoya, Japan (www.gingakobo.jp) and the Wellness Research Institute, Osaka, Japan (www.natural-life.jp).

Abbreviations

QOL, Quality of Life; AAQol, Anti-Aging QOL Common Questionnaire; 8-OHdG, urinary 8-hydroxy-deoxyguanosine; CRE, creatinine; BMI, Body Mass Index; RBC, Red Blood Cells; WBC, White Blood Cells; HGB, hemoglobin content; HCT, hematocrit; GOT, glutamate-oxaloacetate transaminase; GPT, glutamate-pyruvate transaminase; γ -GTP, γ -glutamyl transpeptase; ALP, alkaline phosphatase; CPK, creatinine phosphokinase; CRP, C-reactive protein; BUN, blood urea nitrogen; Cr, blood creatinine; UA, uric acid; T-Chol, total cholesterol; HDL-C, HDL-

cholesterol; LDL-C, LDL-cholesterol; TG, triglycerides; FBS, fasting blood sugar; Hb A1C, glycohemoglobin A1C; DHEA-s, dehydroepiandrosterone sulfate; IGF-I, insulin-like growth factor; LPO, lipid peroxides; MCV, Mean Corpuscular Volume; MCH, Mean Corpuscular Hemoglobin.

References

- [1] Yonei, Y. and Mizuno, Y.: The human dock of tomorrow—Annual health checkup for anti-aging. *Ningen Dock*, **19**, 5–8, 2005.
- [2] Yonei, Y., Mizuno, Y., Togari, H., and Sato, Y.: Muscular resistance training using applied pressure and its effects on the promotion of growth hormone secretion. *Anti-Aging Medical Research*, **1**, 13–27, 2004.
- [3] Yonei, Y., Mizuno, Y., and Katagiri, E.: Effects of cosmetics therapy using isoflavone and pine bark extract on the skin and QOL: A double-blind placebo-controlled trial. *Anti-Aging Medical Research*, **1**, 48–58, 2004.
- [4] Yonei, Y., Iwaita, Y., Muramatsu, K., and Mizuno, Y.: The anti-aging secrets of Japanese executives. *Anti-Aging Medical Research*, **2**, 61–69, 2005.
- [5] Thompson, H.J., Heimendinger, J., Gillette, C., Sedlacek, S.M., Haeghele, A., O'Neill, C., and Wolfe, P.: In vivo investigation of changes in biomarkers of oxidative stress induced by plant food rich diets. *J. Agric. Food Chem.*, **53**, 6126–6132, 2005.
- [6] Urso, M.L. and Clarkson, P.M.: Oxidative stress, exercise, and antioxidant supplementation. *Toxicology*, **189**, 41–54, 2003.
- [7] Piconi, L., Quagliaro, L., and Ceriello, A.: Oxidative stress in diabetes. *Clin. Chem. Lab. Med.*, **41**, 1144–1149, 2003.
- [8] Reda, E., D'Iddio, S., Nicolai, R., Benatti, P., and Calvani, M.: The carnitine system and body composition. *Acta Diabetol.*, **40** Suppl 1, S106–113, 2003.
- [9] Sweeney, J.D. and Arduini, A.: L-carnitine and its possible role in red cell and platelet storage. *Transfus. Med. Rev.*, **18**, 58–65, 2004.
- [10] Alesci, S., De Martino, M.U., Kino, T., and Ilias, I.: L-Carnitine is a modulator of the glucocorticoid receptor alpha. *Ann. NY Acad. Sci.*, **1024**, 147–152, 2004.
- [11] Virmani, A. and Binienda, Z.: Role of carnitine esters in brain neuropathology. *Mol. Aspects Med.*, **25**, 533–549, 2004.
- [12] Saper, R.B., Eisenberg, D.M., and Phillips, R.S.: Common dietary supplements for weight loss. *Am. Fam. Physician*, **70**, 1731–1738, 2004.
- [13] Ferrari, R., Merli, E., Cicchitelli, G., Mele, D., Fucili, A., and Ceconi, C.: Therapeutic Effects of L-Carnitine and Propionyl-L-carnitine on Cardiovascular Diseases: A Review. *Ann. N Y Acad. Sci.*, **1033**, 79–91, 2004.
- [14] Selimoglu, M., Aydogdu, S., Yagci, R.V., and Huseyinov, A.: Plasma and liver carnitine status of children with chronic liver disease and cirrhosis. *Pediatrics International*, **43**, 391–395, 2001.
- [15] Eto, S., Ogawara, S., Kaneoka, H., Tamura, K., Hirose, S., Itoguchi, H., and Saito, T.: Patient Administration of HMG-CoA reductase inhibitor and rising myogenic enzyme levels. *Therapeutic Research*, **23**, 1340–1343, 2002 (in Japanese).
- [16] Heo, Y.-R., Kang, C.-W., and Cha, Y.-S.: L-Carnitine Changes the Levels of Insulin-like Growth Factors (IGFs) and IGF Binding Proteins in Streptozotocin-induced Diabetic Rat. *J. Nutri. Sci. Vitaminol.*, **47**, 329–334, 2001.
- [17] Hayashi, N., Yoshihara, D., Kashiwabara, N., Takeshita, Y., Handa, H., and Yamakawa, M.: Effect of carnitine on decrease of branched chain amino acids and glutamine in serum of septic rats. *Biol. Pharm. Bull.*, **19**, 157–159, 1996.
- [18] Palaniyappan, A. and Chinnakkannu, P.: Replenishment of L-carnitine to aged rats and its effect on glycoprotein. *J. Clin. Biochem. Nutri.*, **26**, 193–200, 1999.
- [19] Izguet-Uysal, V.N., Agac, A., and Derin, N.: Effect of carnitine on stress-induced lipid peroxidation in rat gastric mucosa. *J. Gastroenterol.*, **36**, 231–236, 2001.
- [20] Yoshitoshi, Y.: The effect of Palmitoyl Carnitine on the electrical phenomenon of the cochlea. *Kawasaki Igakukaishi*, **19**, 91–101, 1993 (in Japanese).
- [21] Takada, O.: Early stage, Post Administration of Adrianmycin and movement of carnitine in the myocardium. *Nihon Shouni Junkanki Gakkai Zasshi*, **9**, 800–808, 1994 (in Japanese).
- [22] Yamamoto, M., Lee, J., and Shimizu, H.: Improvement in myocardial metabolism by L-carnitine in the reperfusion rabbit model (making use of ¹H-MRS). *Junkankika*, **35**, 560–563, 1994 (in Japanese).
- [23] Terada, T., Matsubara, T., and Ikoma, Y.: The effect of carnitine on diabetic heart function. *Shinkin Kouzou Taishya*, **14**, 95–99, 1992 (in Japanese).
- [24] Watanabe, S., Ajisaka, R., Masuoka, T., Yamanouchi, T., Saitou, T., Toyama, M., Takeyasu, N., Sakamoto, K., and Sugishita, Y.: Effects of L- and DL-carnitine on patients with impaired exercise tolerance. *Jpn. Heart J.*, **36**, 319–331, 1995.
- [25] Kobayashi, A., Masumura, Y., and Yamazaki, N.: L-carnitine treatment for congestive heart failure—experimental and clinical study. *Jpn. Circ. J.*, **56**, 86–94, 1992.
- [26] Fujiwara, M., Nakano, T., Tamoto, S., Yamada, Y., Fukai, M., Takada, K., Ashida, H., Shimada, T., Ishihara, T., and Seki, I.: Effect of L-carnitine in patients with ischemic heart disease. *Journal of Cardiology*, **21**, 493–504, 1991 (in Japanese).
- [27] Sotohata, I., Noda, S., Hayashi, H., Ito, T., and Mizuno, Y.: Clinical assessment of Levocarnitine chloride (LC-80) administered to angina pectoris patients subjected to treadmill exercise physical tolerance test. *Rinshou Yakurigaku (Clinical Pharmacology)*, **20**, 607–618, 1989 (in Japanese).
- [28] Yoshitoshi, Y., Yamazaki, N., and Imura, K.: Clinical trial of a multicenter double-blind intergroup comparison on the efficacy of Levocarnitine chloride (LC-80) on the pathology of Angina pectoris. *Yakuri To Chiryou*, **17**, 5015–5035, 1989 (in Japanese).
- [29] Endo, S. and Yamamoto, Y.: Study of carnitine replacement therapy for the maintenance of erythropoietin levels in the hemodialysis patient. *Ketsueki Frontier*, **9**, 59–64, 1998 (in Japanese).

- [30] Yamada, M., Niikura, H., Yanagisawa, K., Sone, H., and Shirota, T.: L-carnitine for the dialysis patient. *Nagano-ken Touseki Kenkyukaishi*, **25**, 46–47, 2002 (in Japanese).
- [31] Sugita, T., Saito, Y., Hatano, T., Koizumi, Y., and Kara, T.: Efficacy and safety of metabolic L-Carnitine Plus Diet. *Shinyaku To Rinsho*, **53**, 191–201, 2004.
- [32] Hida, H., Yamada, T., and Yamada, Y.: Production of hydroxycitric acid by microorganisms. *Biosci. Biotechnol. Biochem.*, **69**, 1555–1561, 2005.
- [33] Pessotto, P., Liberati, R., Petrella, O., Romanelli, L., Calvani, M., and Peluso, G.: In experimental diabetes the decrease in the eye of lens carnitine levels is an early important and selective event. *Exp. Eye. Res.*, **64**, 195–201, 1997.
- [34] Alagoz, G., Celiker, U., Ilhan, N., Yekeler, H., Demir, T., and Celiker, H.: L-carnitine in experimental retinal ischemia-reperfusion injury. *Ophthalmologica*, **216**, 144–150, 2002.
- [35] Feher, J., Papale, A., Mannino, G., Gualdi, L., and Balacco Gabrieli, C.: Mitotropic compounds for the treatment of age-related macular degeneration. The metabolic approach and a pilot study. *Ophthalmologica*, **217**, 351–357, 2003.
- [36] Arafa, H.M.: Sayed-Ahmed MM. Protective role of carnitine esters against alcohol-induced gastric lesions in rats. *Pharmacol. Res.*, **48**, 285–290, 2003.